Guelph, ON
ZEN Graphene Solutions Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian, nanotechnology company focused on next-gen healthcare solutions, announces that it has filed a full international patent application for its ZENGuard™ compound under the Patent Cooperation Treaty (PCT). The company elected to file an international patent due to the global opportunities for its technology.
“We believe our ZENGuard™ technology is a key differentiator in the surgical mask market given its antimicrobial properties and its ability to significantly reduce the number of viable bacteria and virus particles that pass through the mask material. The unique, patent-pending science that enables these attributes is related to the bonding between the graphene oxide and silver, where the silver is chelated on its surface,” commented Greg Fenton, CEO.
“Importantly, with the submission of our full international patent, Health Canada approval, and commercial opportunities in front of us, we are working diligently to maximize this opportunity for our shareholders. Further, this is an important demonstration of our ability to complete the journey from scientific breakthrough, patent filing, regulatory approval, then to commercialization. While our immediate focus is on transmission prevention, we look forward to replicating this success with our other healthcare opportunities and beyond. Our focus is to develop innovative nanotechnologies with our partners that improve people’s lives, and we believe our current platform has an unparalleled opportunity to accomplish that.” Mr. Fenton added.
Guelph University also filed a full international patent application under the PCT for the electrochemical exfoliation process to produce graphene oxide; this technology includes automation. ZEN has acquired the exclusive global rights to this technology, and it is being transferred from Guelph University to ZEN’s Research and Develop facility for scale up.
About Zentek Ltd.
Zentek is an ISO 13485‑certified intellectual property development and commercialization company that builds and advances distinct brands in filtration, biosciences and critical minerals using graphene‑based nanomaterials and aptamer technologies.
Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
To find out more about Zentek, please visit www.zentek.com. A copy of this news release and other material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at www.sedarplus.ca.
Forward-Looking Statements
This news release contains forward‑looking statements. Since forward‑looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward‑looking statements. Such risks and uncertainties include, but are not limited to, operational risks in exploration, development and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainties involved in the discovery and delineation of mineral deposits, resources or reserves; the uncertainty of resource and reserve estimates and the ability to economically exploit resources and reserves; the uncertainty of estimates and projections in relation to production, costs and expenses; the uncertainty surrounding the ability of the Company to obtain all permits, consents or authorizations required for its operations and activities; market and regulatory risks; and health, safety and environmental risks. Although Zentek believes that the assumptions and factors used in preparing the forward‑looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward‑looking information, whether as a result of new information, future events or otherwise, other than as required by law. Further studies, financing, permits and approvals would be required before a production decision Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.